Inventor · disambiguated record
Sonja Schrepfer
Also filed as: SCHREPFER SONJA
8 granted patents·24 pending applications·13 citations·filing 2014–2025
80Inventor score
Top patents by PatentIndex Score
32 records- 0191US12221622B2Modified pluripotent cellsUNIV CALIFORNIA·Filed 2020·Granted Feb 11, 2025·3 cites·70 claims
- 0291US11162079B2Blood type O Rh-hypo-immunogenic pluripotent cellsUNIV CALIFORNIA·Filed 2020·Granted Nov 2, 2021·7 cites·22 claims
- 0388US11802157B2Methods and compositions for modulating CAR-T activitySANA BIOTECHNOLOGY INC·Filed 2022·Granted Oct 31, 2023·1 cites·27 claims
- 0480US11987628B2Methods and compositions for modulating CAR-T activitySANA BIOTECHNOLOGY INC·Filed 2023·Granted May 21, 2024·0 cites·30 claims
- 0580US2025019433A1Methods and compositions for modulating car-t activitySANA BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 0676US9480666B2Compositions and methods for inhibiting intimal hyperplasiaDEUSE TOBIAS·Filed 2015·Granted Nov 1, 2016·2 cites·18 claims
- 0775US11965022B2Methods and compositions for modulating CAR-T activitySANA BIOTECHNOLOGY INC·Filed 2021·Granted Apr 23, 2024·0 cites·20 claims
- 0871US2023348862A1Immunoengineered pluripotent cellsUNIV CALIFORNIA·Filed 2023·Application pending·0 cites
- 0969US12492382B2Blood type O Rh—hypo-immunogenic cellsUNIV CALIFORNIA·Filed 2021·Granted Dec 9, 2025·0 cites·22 claims
- 1064US2025223564A1Hypoimmune beta cells differentiated from pluripotent stem cells and related uses and methodsSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1162US2023293581A1Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositionsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 1262US2024010988A1Genetically modified primary cells for allogeneic cell therapySANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1362US2022049226A1Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositionsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 1461US2025127820A1Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactionsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 1561US2024425820A1Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactionsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 1659US2025283051A1Cells differentiated from immunoengineered pluripotent cellsUNIV CALIFORNIA·Filed 2025·Application pending·0 cites
- 1759US2024226164A1Hypoimmunogenic cells comprising engineered hla-e or hla-gSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 1859US2025302876A1Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methodsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 1958US2024358761A1Genetically modified cells for allogeneic cell therapySANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2058US2024316198A1Altered expression of y chromosome-linked antigens in hypoimmunogenic cellsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2157US2024252642A1Hypoimmunogenic rhd negative primary t cellsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2257US2021292715A1Cells differentiated from immunoengineered pluripotent cellsUNIV CALIFORNIA·Filed 2019·Application pending·0 cites
- 2356US2023272429A1Modification of blood type antigensSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 2454US2025320290A1METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPalpha BLOCKADE AGENTSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 2553US2016296561A1Regulatory macrophages as a cell-based immunomodulatory therapy in pulmonary hypertension and right ventricular dysfunctionUNIV LELAND STANFORD JUNIOR·Filed 2014·Application pending·0 cites
- 2652US2023293593A1Hypoimmunogenic neural cells for the treatment of neurological disorders and conditionsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 2752US2023174935A1Repeat dosing of hypoimmunogenic cellsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 2850US2022267732A1Dux4 expressing cells and uses thereofSANA BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 2949US10016378B2Compositions and methods for inhibiting intimal hyperplasiaDEUSE TOBIAS·Filed 2016·Granted Jul 10, 2018·0 cites·20 claims
- 3049US2021308183A1Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cellsUNIV CALIFORNIA·Filed 2019·Application pending·0 cites
- 3147US2023025289A1Cd24 expressing cells and uses thereofSANA BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 3246US2019376045A1Immunoengineered pluripotent cellsUNIV CALIFORNIA·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sonja Schrepfer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →